{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T12:10:17Z","timestamp":1775995817238,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T00:00:00Z","timestamp":1429574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,1]]},"abstract":"Abstract<\/jats:title>Nucleophosmin (NPM<\/jats:styled-content>1<\/jats:italic>) mutations in chronic myelomonocytic leukemia (CMML<\/jats:styled-content>) are extremely uncommon, and the clinicopathologic features of these neoplasms are poorly characterized. Over a 10\u2010yr interval, NPM<\/jats:styled-content>1<\/jats:italic> mutation analysis was performed in 152 CMML<\/jats:styled-content> at our institution. NPM<\/jats:styled-content>1<\/jats:italic> mutations were identified in 8 (5.3%) patients, five men and three women, with a median age of 72\u00a0yr (range, 27\u201387). In all patients, the bone marrow was hypercellular with multilineage dysplasia, monocytosis, and retained maturation supporting a diagnosis of CMML<\/jats:styled-content>. NPM<\/jats:styled-content>1<\/jats:italic> mutation allele burden was <5% in two patients and >10% in six patients. Four (50%) patients, all with >10% NPM<\/jats:styled-content>1,<\/jats:italic> progressed AML<\/jats:styled-content> with a median interval of 11\u00a0months (range, 1\u201321). Compared with 144 CMML<\/jats:styled-content> without NPM<\/jats:styled-content>1<\/jats:italic> mutations, CMML<\/jats:styled-content> patients with NPM<\/jats:styled-content>1<\/jats:italic> mutation presented with more severe anemia (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.053), higher BM<\/jats:styled-content> monocyte percentage (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.033), and an increased tendency for AML<\/jats:styled-content> progression (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.088) and an inferior overall survival (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.076). Mutations involving NRAS<\/jats:styled-content>\/KRAS<\/jats:styled-content> (2\/7), TET<\/jats:styled-content>2(2\/5), ASXL<\/jats:styled-content>1(1\/5,) and FLT<\/jats:styled-content>3(0\/8)<\/jats:italic> were not significantly different between these two groups. In summary, CMML<\/jats:styled-content> with NPM<\/jats:styled-content>1<\/jats:italic> mutation shows histopathological features of CMML<\/jats:styled-content>, but patients appear to have a high probability for AML<\/jats:styled-content> progression and may require aggressive clinical intervention, especially in patients with a high mutation burden.<\/jats:p>","DOI":"10.1111\/ejh.12549","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T21:37:46Z","timestamp":1427233066000},"page":"65-71","source":"Crossref","is-referenced-by-count":49,"title":["Chronic myelomonocytic leukemia with nucleophosmin (NPM<\/scp>1<\/i>) mutation"],"prefix":"10.1111","volume":"96","author":[{"given":"Jie","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Hematology Central South University Xiangya Hospital Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Hematology Central South University Xiangya Hospital Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitrayee","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Priyanka","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Muzzafar","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.4274\/Tjh.2013.0023"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2240"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3167"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32801684c7"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1496"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23404"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2248"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2164"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2174"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_5_14_1","unstructured":"2008 International Agency for Research on Cancer (IARC) Lyon ABJ Orazi U Germing RD Brunning BJ Bain J Thiele WHO classification of tumours of haematopoietic and lymphoid tissues 76 9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.05.015"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103960"},{"key":"e_1_2_5_17_1","first-page":"1147","article-title":"Mutations and promoter methylation status of NPM1 in myeloproliferative disorders","volume":"91","author":"Oki Y","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06081.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.021808"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.218"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491399"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPEI9XU8PYBCIO"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.05.003"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.299"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205708"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03915"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01710.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12549","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:38:59Z","timestamp":1695742739000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/ejh.12549"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12549","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,21]]}}}